Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-06-03T10:33:10.018Z Has data issue: false hasContentIssue false
  • English
  • Français

2218 – Brain-derived Neurotrophic Factor Gene Polymorphism (val66met) And The Response To Escitalopram In Depression

Published online by Cambridge University Press:  15 April 2020

W. El-Hage
W. El-Hage*
Affiliation:
INSERM U930 ERL, Université François Rabelais & CHRU, Tours, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The Brain-derived neurotrophic factor (BDNF) gene is a candidate gene for influencing the clinical response to treatment with antidepressants.

Objective

The aim of the study was to determine the effects of 3 and 6 weeks of escitalopram treatment in depressed patients subdivided according to the treatment response.

Methods

We included 188 French subjects with depression, 153 completed a 6-week treatment with escitalopram (10–20 mg/d). Clinical evaluation was performed using the Montgomery and Asberg Depression Rating Scale (MADRS) before treatment and after 3 and 6 weeks of treatment.

Results

At 3 weeks of escitalopram treatment, the Met carriers had increased antidepressant response in comparison to Val/Val homozygotes. No significant clinical difference between genotype groups remained at 6 weeks of escitalopram treatment.

Conclusions

Our findings further support that the Brain-Derived Neurotrophic Factor gene polymorphism (Val66Met) may play a role in antidepressant treatment response phenotypes in mood depressive episode.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E1378
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.